At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.
Michael Wang, MD
Advertisement
Articles by Michael Wang, MD
At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss
2
Multi-Stakeholder Collaboration Is Essential to Achieve Equity in IPF Care
3
Duration of Response With Sonrotoclax Vs Current Therapies for MCL
4
Cost-Effective Strategies for Depression Management at AMCP Nexus
5
